Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

NCT04923932 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Esophagogastric Junction Disorder

Interventions

DRUG: Savolitinib

Sponsor

Hutchison Medipharma Limited